Target prioritization frameworks tend to be built around the question of which target has the strongest biological evidence. That is the right question in principle, but it ignores a second question that is equally important in practice: which target is executable given your team's actual capacity and budget? The interaction between these two questions determines which target you should actually work on next.
Why Capacity Constraints Should Influence Ranking
A target with outstanding genetic and functional evidence is only the right choice if your team has the assay capabilities to actually investigate it. A kinase with a strong GWAS signal is a less attractive first target for a team with no kinase assay infrastructure than a gene in a pathway they have established models for. The evidence quality is a fixed property of the target; the execution cost is a property of your specific team's situation, and it changes the expected value calculation substantially.
Similarly, a target whose validation requires expensive high-content imaging infrastructure is a different proposition for a team with a lean runway than for a group with an established imaging core. The expected value calculation changes when you factor in assay development time and cost. A target that requires six months of assay development before you get the first interpretable data point consumes half a year before you have learned anything about whether the target is actually worth pursuing.
The Capacity-Adjusted Priority
A useful mental model is to think of target priority as a product of evidence quality and execution feasibility. A target that scores 0.85 on biological evidence but requires six months of assay development might rank below a target with a 0.72 score that can be moved into wet-lab work in three weeks. The difference in speed-to-data has downstream effects on the whole program timeline, and speed-to-data is itself a form of evidence value: the faster you get signal, the sooner you can update your target ranking with real functional data.
For early-stage teams, execution feasibility includes not just assay infrastructure but also reagent availability, timeline to validated cell models, and whether the needed expertise is on staff or requires external collaboration. A target that requires a specialized transgenic model takes longer than one that can be characterized in an established human cell line. These practical differences translate directly into program timelines and resource consumption.
Sequencing vs Parallel Investigation
Small teams often have to choose between investigating one target deeply and pursuing two in parallel at shallower depth. The right choice depends on the shape of the evidence: if two targets both have moderate confidence and the evidence types are independent, parallel shallow investigation that can quickly exclude one is often more efficient than sequentially investigating each in full depth. If one target has strong evidence and the other weak, serial deep investigation of the stronger target first is usually better -- you learn more per unit of resource spent.
This sequencing logic is something that gets lost in frameworks that only look at biological evidence scores. Confidence scores are a starting point; the execution context completes the picture. A team that selects based solely on evidence scores without considering execution dependencies often finds itself mid-program in an assay development bottleneck that could have been anticipated and planned around.
Budget as Evidence
The title of this piece frames bench budget as a constraint rather than as evidence, but there is a sense in which it is both. A target that requires expensive reagents, specialized equipment, or rare cell models to evaluate has also been selected against by the field -- historically, targets have been less pursued when they were technically difficult to study, which means their evidence base is thinner than it would be if they were easy to study. Technical difficulty correlates with literature sparsity, and literature sparsity contributes to lower confidence scores.
This means that some of the most interesting targets -- technically underexplored due to historical difficulty -- may appear lower-confidence than they deserve, and may also be the most expensive to investigate initially. The right response is not to systematically avoid these targets but to be explicit about the tradeoff: higher upside potential, higher cost of initial characterization, and a longer timeline before you have interpretable data.
Practical Implication for Target List Review
When reviewing a ranked target list with your team, the conversation should not just be "do we agree this target ranks first?" It should also be "given our current infrastructure and timeline, which of the top five candidates is most executable?" For a team with a specific assay background, the fifth-ranked target may be genuinely more achievable than the first-ranked one. If the evidence gap is within the normal range of uncertainty, the execution advantage may outweigh the difference in evidence quality.
The goal is not to systematically favor easy targets over well-evidenced ones but to make the capacity tradeoff explicit rather than invisible. Teams that ignore execution feasibility in favor of pure evidence ranking often end up with programs that stall at assay development while a more tractable candidate waits. Making the tradeoff visible lets the team decide it deliberately rather than stumbling into it.
Integrating Capacity into Scoring
Some teams handle this informally by applying a veto to the top-ranked target if it is infeasible. That is better than ignoring capacity entirely, but it does not capture the continuous tradeoff between evidence quality and execution cost. A more systematic approach is to maintain a separate feasibility assessment for each candidate alongside the evidence score, and to make the interaction between them explicit in team discussions about which programs to start.
Feasibility dimensions worth assessing explicitly include: existing assay infrastructure for the target class, availability of validated reagents (antibodies, CRISPR guides, chemical probes), timeline and cost to establish a primary cell-based assay, need for specialized equipment or core facility access, and whether the key experimental expertise is in-house or requires a collaboration. Each of these is estimable with reasonable accuracy by a team member familiar with the specific target, and the estimates are much more useful when they are written down than when they exist only as informal intuitions.
The output of this assessment is not a single feasibility score but a structured description of what it would take to begin wet-lab work on each candidate. That description, reviewed alongside the evidence score, gives the team the information it needs to make a principled prioritization decision rather than a purely intuition-driven one.